Events

Wellbeing at Work Summit w/ Rohan Kallicharan

Panel Discussion: Successful International Wellbeing Strategies

5th November | 9:50 - 10.25

Join BenevolentAI’s HR Director and Mind campaigner, Rohan for a panel discussion on the secrets to achieving international wellbeing strategy success.

Register →


Rohan Kallicharan
HR Director

Rohan is HR Director at BenevolentAI and an ambassador for Mind, the mental health charity. He has advised a number of high profile companies on their mental wellbeing strategy, as well as involvement in national campaigns to raise awareness around mental health.Recently, he has worked with the FA, Heads Together and Kensington Palace, speaking to Sky News, the BBC and ITV about his own journey from severe mental illness and homelessness to advocacy, and championing the significant role of sport and football in breaking down barriers in talking about mental wellbeing, especially for young men.

More Posts

You Might Also Like

News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021
News
BenevolentAI named as one of Fierce Medtech’s Fierce 15 of 2020
BenevolentAI was selected as one of the most promising private companies in the industry by Fierce Medtech in its Fierce 15 2020 list.
Mar 8, 2021
Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021
News
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.
Jan 27, 2021
News
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021